Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant (SAFIA)
Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®
Sponsor: AstraZeneca
This PHASE3 trial investigates Breast Neoplasm Female and is currently completed. AstraZeneca leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Apr 2023 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Genomic Health®, Inc.
- International Cancer Research Group, United Arab Emirates
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Al Ain City, United Arab Emirates , Alexandria, Egypt , Algiers, Algeria , Amman, Jordan , Beirut, Lebanon , Blida, Algeria , Cairo, Egypt , Casablanca, Morocco , Oran, Algeria , Rabat, Morocco and 2 more locations